Search
for
Sort by
Research 331–360 of 1000+
- PSS34 THE IMPACT OF POTENTIAL PILL SPLITTING ON GENERIC AND BRANDED FINASTERIDE UPTAKE
- Alopecia Areata is associated with MICA and an extended HLA haplotype
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Hair Aging Revisited: An Expert Delphi Consensus on Pathogenesis, Clinical Features, and Future Therapies
- Cutaneous manifestations of COVID-19 and vaccines for its prevention: a review of the existing literature
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
- All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
- Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA
- The genetic basis of dermatophytosis skin infection susceptibility
- Geriatric Dermatologic Therapy
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- The Intersection of Sleep and Hair Loss: A Systematic Review
- Non-scarring Alopecia in Pemphigus Foliaceus
- Epidemiology and burden of alopecia areata in Taiwan: a systematic review
- Scalp cooling and chemotherapy-induced alopecia: Evaluating cost-effectiveness and insurance coverage
- Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging
- Farmácia Boa Hora - Porto
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Farmácia Sanches - Leiria e nos Serviços Farmacêuticos do Hospital Lusíadas - Porto
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review